Iovance Reports Third-Quarter 2026 Revenue of About $122 Million
Iovance said total revenue increased about 80% year over year and U.S. Amtagvi revenue rose about 77%.
Story updates
12:19:14 PM UTC
SquawkNews
Iovance Biotherapeutics reported third-quarter 2026 revenue of $121.5 million, up about 80% year over year, and a gross margin of approximately 60%. The company reported an operating loss of $24.0 million and a net loss of $22.3 million, or $0.05 per diluted share. Iovance maintained its 2026 reven…